Kreuter, Michael
Koegler, Harald
Trampisch, Matthias
Geier, Silke
Richeldi, Luca
Funding for this research was provided by:
Boehringer Ingelheim
Article History
Received: 17 May 2018
Accepted: 28 March 2019
First Online: 11 April 2019
Ethics approval and consent to participate
: The INPULSIS® trials were conducted in accordance with the principles of the Declaration of Helsinki and the Harmonized Tripartite Guideline for Good Clinical Practice from the International Conference on Harmonization and were approved by local authorities. The clinical protocol was approved by an independent ethics committee or institutional review board at each participating centre. All patients provided written informed consent before study entry.
: Not applicable.
: HK, MT, SG are employees of Boehringer Ingelheim. LR reports grants and personal fees from InterMune, and personal fees from Boehringer Ingelheim, Biogen, Cipla, ImmuneWorks, MedImmune, Pliant Therapeutics, Roche, Sanofi-Aventis, Shionogi, and Takeda. MK and his institution received grants and reimbursement for speakers bureaus and consulting from Boehringer Ingelheim and Roche and fees for consulting from Galapagos.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.